Nicorandil elevates tissue cGMP levels in a nitric-oxide-independent manner

Journal of Pharmacological Sciences

Volumn 103, Issue 1, 2007, Pages 33-39

  Minamiyama, Yukiko ^a,b   Takemura, Shigekazu ^b   Hai, Seikan ^b   Suehiro, Shigefumi ^b   Okada, Shigeru ^a   Funae, Yoshihiko ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cGMP; Nicorandil; Nitric oxide (NO); P450

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; CYCLIC GMP; CYTOCHROME P450; GLYCERYL TRINITRATE; ISOBUTYLMETHYLXANTHINE; N ACETYL S NITROSOPENICILLAMINE; NICORANDIL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; GENETIC TRANSFECTION; HEART; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CYTOSOL; LIVER HOMOGENATE; LIVER MICROSOME; LIVER PARENCHYMA; LIVER PERFUSION; MALE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER;

EID: 33846561976     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0061003     Document Type: Article

References (19)

1. Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs. 2004;64:1941-1955.
2. Armstrong PW, Moffat JA. Tolerance to organic nitrates: clinical and experimental perspectives. Am J Med. 1983;74:73-84.
3. Munzel T, Kurz S, Heitzer T, Harrison DG. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996;77:24C-30C.
4. Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol. 1992;20 Suppl 3:S86-S92.
5. Tabone X, Funck-Brentano C, Billon N, Jaillon P. Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. Clin Pharmacol Ther. 1994;56:672-679.
6. Dendorfer A. [Pharmacology of nitrates and other NO donors.] Herz. 1996;21 Suppl 1:38-49. (text in German with English abstract)
7. Torfgard KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther. 1994;8:701-717.
8. Feelisch M. [Nitrogen monoxide (NO) - the active principle of organic nitrates.] Schweiz Rundsch Med Prax. 1993;82:1167-1171. (text in German with English abstract)
9. Chen Z, Foster MW, Zhang J, Mao L, Rockman HA, Kawamoto T, et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159-12164.
10. Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y, et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999;452:165-169.
11. Pastor CM, Billiar TR. Regulation and functions of nitric oxide in the liver in sepsis and inflammation. New Horiz. 1995;3:65-72.
12. Sakai K, Akima M, Saito K, Saitoh M, Matsubara S. Nicorandil metabolism in rat myocardial mitochondria. J Cardiovasc Pharmacol. 2000;35:723-728.
13. Goldschmidt M, Landzberg BR, Frishman WH. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. J Clin Pharmacol. 1996;36:559-572.
14. Greenberg SS, Cantor E, Ho E, Walega M. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters. J Pharmacol Exp Ther. 1991;258:1061-1071.
15. Endoh M, Yanagisawa T, Taira N. Effects of 2-nicotinamidethyl nitrate (SG-75), a new antianginal drug, on the cyclic AMP phosphodiesterase activity. Tohoku J Exp Med. 1980;130:199-201.
16. Ishizuka N, Saito K, Akima M, Matsubara S, Saito M. Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. Jpn J Pharmacol. 2000;84:316-324.
17. Newgreen DT, Bray KM, McHarg AD, Weston AH, Duty S, Brown BS, et al. The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim. Br J Pharmacol. 1990;100:605-613.
18. Southerton JS, Weston AH, Bray KM, Newgreen DT, Taylor SG. The potassium channel opening action of pinacidil; studies using biochemical, ion flux and microelectrode techniques. Naunyn Schmiedebergs Arch Pharmacol. 1988;338:310-318.
19. Weston AH, Bray KM, Duty S, McHarg AD, Newgreen DT, Southerton JS. In vitro studies on the mode of action of pinacidil. Drugs. 1988;36 Suppl 7:10-28.